Entries Tagged as ''

National Attention To Medical Bills Not Owed After Insurance Payments

Recently there has been some helpful national attention to the issue of balance billing by medical providers. The issue being medical bills patients are receiving after their insurance company has reduced the bill to a fee schedule. The providers should be fighting the issue out with the insurance company. Instead bills are sent to the patent. It is suspected that patients may have wrongfully paid as much as a billion dollars in bills they don't owe.

The issue was coveruddy in a recent Business Weekly article and also coveruddy in recent television news stories on CBS. The CBS story found that in 2007, 1.7 million people in California had been balanced billed 528 million. Each story had significant human interest examples of people that were chased by collection agencies in States were it simple shouldn't have happened.

There are federal laws that prevent this billing when Medicare is the Insurance company. In Minnesota there are laws that cover Medical Assistance payments and other laws that prevent abusive or fradualent billing practices. There are exceptions for consmetic surgery and out of network non-referal non emergancy care.

The key is that beyond your co pays , make sure that any additional bills are actually legally due and payable. If you have a question you can contact the Attorney General, The Department of Commerse or Call an attorney that practices in this area.


Originally posted at InjuryBoard by Mike Bryant

New Hope Sparked By Ovarian Cancer Test

LabCorp, a major clinical laboratory company, offers a new blood test for early detection of ovarian cancer. The test was developed at Yale and is called OvaSure. Right now, symptoms such as pain and bloating are possible indicators of cancer, but those symptoms can also signal other conditions. Also, those symptoms may occur after the cancer has progressed. The American Cancer Society reports that this year over 21,000 women will be diagnosed with ovarian cancer, and 15,000 of them will likely die from the disease. Ninety percent of women whose cancer is detected at its earliest stages will reach the five year survival mark. But only 30 percent of women will live for five years if their cancer is detected in its latest stages.

These statistics demonstrate why it is so important to detect ovarian cancer early and why the availability of an early detection test raises hope among women and their doctors. However, there are also concerns raised by the OvaSure test. A statement issued by the Society of Gynocologic Oncologists reported that the test had not been validated enough for routine use. OvaSure was not reviewed by the FDA because generally the agency does not regulate tests developed and performed by a single laboratory, such as in this case. Last month, the FDA issued a letter to LabCorp, requesting more data about OvaSure. In addition, the FDA plans to regulate complex tests like OvaSure, but currently the policy is not finalized.

Originally posted at InjuryBoard by Jamie Sheller